Innovation-driven biopharma startup Lamark Biotech has secured Rs 6.5 crore in a pre-Sequence A funding spherical. IAN Group led the funding, with participation from IAN Alpha Fund, powered by BioAngels, together with Dr. Vinayender Tulla, Dr. Nita Roy, and Venkataraman KNK—area specialists and angel traders from IAN.
Dr. Vaibhav Bhatia, a biochemist and entrepreneur, based Lamark Biotech in 2018 with a imaginative and prescient to revolutionise drug supply for continual and life-altering circumstances. The corporate’s proprietary ProteoStrong platform stabilises delicate protein-based medicine, equivalent to insulin, monoclonal antibodies, and enzymes with out altering their molecular construction, thus addressing a significant problem in biologics: decreasing reliance on cold-chain logistics.
“We’re accelerating our thermostable insulin program and increasing ProteoStrong to extra important therapeutics utilizing this useful resource. Our precedence is evident to make secure and high-efficacy biologics for all. We consider, ‘if it isn’t accessible, it not a medication’,” mentioned Vaibhav Bhatia, who additionally serves as the corporate’s CEO.
Padmaja Ruparel, Co-founder of IAN Group, famous, “Funding in Lamark represents IAN’s funding technique to take a position and develop improvements that resolve actual issues. The answer is important in low-resource environments, with Lamark’s thermostable biologics which might make important therapies accessible at a low price for tens of millions of individuals, each in India and globally.”
Headquartered in Ahmedabad and working out of the Enterprise Centre at NCL Innovation Park in Pune, Lamark is growing a novel class of temperature-resilient biologics able to retaining effectiveness even in excessive circumstances. These are significantly well-suited for areas missing chilly storage infrastructure.
With its flagship program, InsulinStrong, Lamark goals to seize a share of India’s Rs 4,000 crore insulin market and develop into Southeast Asia and the UAE. The corporate can also be advancing purposes of its platform in diabetic eye illness and most cancers immunotherapy.
Over the following two years, Lamark plans to file worldwide patents, launch early-stage scientific trials, and forge collaborations with pharmaceutical companies, CDMOs, and international well being organisations.
Prepared to take a position like a professional? Unicorn Indicators app equips you with 100+ Free instruments and data it’s good to succeed. Obtain the Unicorn Indicators app and achieve entry to every day inventory lists and insightful market evaluation and way more!
